195 related articles for article (PubMed ID: 36550260)
1. CRISPR-Cas9 mediated genome editing of Huntington's disease neurospheres.
Han JY; Seo J; Choi Y; Im W; Ban JJ; Sung JJ
Mol Biol Rep; 2023 Mar; 50(3):2127-2136. PubMed ID: 36550260
[TBL] [Abstract][Full Text] [Related]
2. CRISPR/Cas9 Mediated Therapeutic Approach in Huntington's Disease.
Alkanli SS; Alkanli N; Ay A; Albeniz I
Mol Neurobiol; 2023 Mar; 60(3):1486-1498. PubMed ID: 36482283
[TBL] [Abstract][Full Text] [Related]
3. Nicotinamide improves motor deficits and upregulates PGC-1α and BDNF gene expression in a mouse model of Huntington's disease.
Hathorn T; Snyder-Keller A; Messer A
Neurobiol Dis; 2011 Jan; 41(1):43-50. PubMed ID: 20736066
[TBL] [Abstract][Full Text] [Related]
4. Compensatory changes in the ubiquitin-proteasome system, brain-derived neurotrophic factor and mitochondrial complex II/III in YAC72 and R6/2 transgenic mice partially model Huntington's disease patients.
Seo H; Kim W; Isacson O
Hum Mol Genet; 2008 Oct; 17(20):3144-53. PubMed ID: 18640989
[TBL] [Abstract][Full Text] [Related]
5. Generation of New Isogenic Models of Huntington's Disease Using CRISPR-Cas9 Technology.
Dabrowska M; Ciolak A; Kozlowska E; Fiszer A; Olejniczak M
Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32182692
[TBL] [Abstract][Full Text] [Related]
6. CRISPR-Cas9 Mediated Gene-Silencing of the Mutant Huntingtin Gene in an In Vitro Model of Huntington's Disease.
Kolli N; Lu M; Maiti P; Rossignol J; Dunbar GL
Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28368337
[TBL] [Abstract][Full Text] [Related]
7. Base editing strategies to convert CAG to CAA diminish the disease-causing mutation in Huntington's disease.
Choi DE; Shin JW; Zeng S; Hong EP; Jang JH; Loupe JM; Wheeler VC; Stutzman HE; Kleinstiver B; Lee JM
Elife; 2024 Jun; 12():. PubMed ID: 38869243
[TBL] [Abstract][Full Text] [Related]
8. A selective inhibitor of the NLRP3 inflammasome as a potential therapeutic approach for neuroprotection in a transgenic mouse model of Huntington's disease.
Chen KP; Hua KF; Tsai FT; Lin TY; Cheng CY; Yang DI; Hsu HT; Ju TC
J Neuroinflammation; 2022 Feb; 19(1):56. PubMed ID: 35219323
[TBL] [Abstract][Full Text] [Related]
9. CRISPR-Cas9-Mediated Genome Editing Increases Lifespan and Improves Motor Deficits in a Huntington's Disease Mouse Model.
Ekman FK; Ojala DS; Adil MM; Lopez PA; Schaffer DV; Gaj T
Mol Ther Nucleic Acids; 2019 Sep; 17():829-839. PubMed ID: 31465962
[TBL] [Abstract][Full Text] [Related]
10. CRISPR/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington's disease.
Yang S; Chang R; Yang H; Zhao T; Hong Y; Kong HE; Sun X; Qin Z; Jin P; Li S; Li XJ
J Clin Invest; 2017 Jun; 127(7):2719-2724. PubMed ID: 28628038
[TBL] [Abstract][Full Text] [Related]
11. Neuroprotective effects of PPAR-γ agonist rosiglitazone in N171-82Q mouse model of Huntington's disease.
Jin J; Albertz J; Guo Z; Peng Q; Rudow G; Troncoso JC; Ross CA; Duan W
J Neurochem; 2013 May; 125(3):410-9. PubMed ID: 23373812
[TBL] [Abstract][Full Text] [Related]
12. The potential of gene editing for Huntington's disease.
Duan W; Urani E; Mattson MP
Trends Neurosci; 2023 May; 46(5):365-376. PubMed ID: 36907678
[TBL] [Abstract][Full Text] [Related]
13. Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration.
Weydt P; Pineda VV; Torrence AE; Libby RT; Satterfield TF; Lazarowski ER; Gilbert ML; Morton GJ; Bammler TK; Strand AD; Cui L; Beyer RP; Easley CN; Smith AC; Krainc D; Luquet S; Sweet IR; Schwartz MW; La Spada AR
Cell Metab; 2006 Nov; 4(5):349-62. PubMed ID: 17055784
[TBL] [Abstract][Full Text] [Related]
14. Subcellular Localization And Formation Of Huntingtin Aggregates Correlates With Symptom Onset And Progression In A Huntington'S Disease Model.
Landles C; Milton RE; Ali N; Flomen R; Flower M; Schindler F; Gomez-Paredes C; Bondulich MK; Osborne GF; Goodwin D; Salsbury G; Benn CL; Sathasivam K; Smith EJ; Tabrizi SJ; Wanker EE; Bates GP
Brain Commun; 2020; 2(2):fcaa066. PubMed ID: 32954323
[TBL] [Abstract][Full Text] [Related]
15. Expression profiling of Huntington's disease models suggests that brain-derived neurotrophic factor depletion plays a major role in striatal degeneration.
Strand AD; Baquet ZC; Aragaki AK; Holmans P; Yang L; Cleren C; Beal MF; Jones L; Kooperberg C; Olson JM; Jones KR
J Neurosci; 2007 Oct; 27(43):11758-68. PubMed ID: 17959817
[TBL] [Abstract][Full Text] [Related]
16. CRISPR-Based Genome-Editing Tools for Huntington's Disease Research and Therapy.
Qin Y; Li S; Li XJ; Yang S
Neurosci Bull; 2022 Nov; 38(11):1397-1408. PubMed ID: 35608753
[TBL] [Abstract][Full Text] [Related]
17. Targeting CAG repeat RNAs reduces Huntington's disease phenotype independently of huntingtin levels.
Rué L; Bañez-Coronel M; Creus-Muncunill J; Giralt A; Alcalá-Vida R; Mentxaka G; Kagerbauer B; Zomeño-Abellán MT; Aranda Z; Venturi V; Pérez-Navarro E; Estivill X; Martí E
J Clin Invest; 2016 Nov; 126(11):4319-4330. PubMed ID: 27721240
[TBL] [Abstract][Full Text] [Related]
18. Brain-derived neurotrophic factor over-expression in the forebrain ameliorates Huntington's disease phenotypes in mice.
Gharami K; Xie Y; An JJ; Tonegawa S; Xu B
J Neurochem; 2008 Apr; 105(2):369-79. PubMed ID: 18086127
[TBL] [Abstract][Full Text] [Related]
19. Cas9-mediated replacement of expanded CAG repeats in a pig model of Huntington's disease.
Yan S; Zheng X; Lin Y; Li C; Liu Z; Li J; Tu Z; Zhao Y; Huang C; Chen Y; Li J; Song X; Han B; Wang W; Liang W; Lai L; Li XJ; Li S
Nat Biomed Eng; 2023 May; 7(5):629-646. PubMed ID: 36797418
[TBL] [Abstract][Full Text] [Related]
20. Precise Excision of the CAG Tract from the Huntingtin Gene by Cas9 Nickases.
Dabrowska M; Juzwa W; Krzyzosiak WJ; Olejniczak M
Front Neurosci; 2018; 12():75. PubMed ID: 29535594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
